Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation
John Nixon, Paul Newbold, Tomas Mustelin, Gary P Anderson, Roland Kolbeck
PHARMACOLOGY & THERAPEUTICS | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2017
Eosinophils have been linked with asthma for more than a century, but their role has been unclear. This review discusses the roles of eosinophils in asthma and chronic obstructive pulmonary disease (COPD) and describes therapeutic antibodies that affect eosinophilia. The aims of pharmacologic treatments for pulmonary conditions are to reduce symptoms, slow decline or improve lung function, and reduce the frequency and severity of exacerbations. Inhaled corticosteroids (ICS) are important in managing symptoms and exacerbations in asthma and COPD. However, control with these agents is often suboptimal, especially for patients with severe disease. Recently, new biologics that target eosinophili..View full abstract
Related Projects (1)
Editing assistance was provided by Elizabeth Strickland, PhD, of JK Associates, Conshohocken, PA, and Michael A. Nissen, ELS, of AstraZeneca, Gaithersburg, MD. This assistance was funded by AstraZeneca, Gaithersburg, MD, USA.